By Deena Beasley (Reuters) -CVS Health, which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' ...

CVS Health (CVS) won't include Gilead's (GILD) new HIV drug Yeztugo in its commercial healthcare plans, due to clinical, ...

CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing nearly $290 million in Medicare overcharge penalties.

Gilead Sciences (NASDAQ:GILD) stock fell 2.7% in pre-market trading Thursday after reports that CVS Health (NYSE:CVS) will not add the company’s new HIV prevention drug, Yeztugo, to its commercial ...

Investing.com -- CVS Health (NYSE: CVS) will not include Gilead Sciences (NASDAQ: GILD )’ new HIV prevention drug Yeztugo in its commercial plans for the time being, despite the medication’s proven ...

The company is also navigating activist criticism over access to Yeztugo and ongoing negotiations with Gilead, even as U.S.

Retailers in the U.S. are increasingly cautious due to tariffs and destocking inventories as cost-conscious consumers tighten ...

Industries to Neutral from Buy after the building materials company reported weaker quarterly earnings and lowered its guidance on North America, its largest market.

Investing.com -- Amazon extended its lead in the U.S. e-commerce market in the second quarter, according to JPMorgan (NYSE:JPM), which cited the company’s accelerating retail growth and logistics ...